Oxford Biosystems - SD Biosensor

Reducing the impact of serious infections is an aim that manufacturers and suppliers of point of care tests take very seriously. SD Biosensor (Korea) is a company specialising in the development of in vitro diagnostics to provide fast and accurate diagnosis of infection.

New to the UK, their Standard F system is a compact, easy to use, multi-parametric and random accessible fluorescent immunoassay system designed for near patient testing. The current test portfolio includes infectious diseases, biomarkers for inflammation, chronic and cardiac diseases. The rapid detection of respiratory pathogens direct from sample is of great benefit in infection control, and the new Procalcitonin (PCT) test enables screening for a key indicator of Sepsis to be performed within minutes. With an automatic direct download of results possible to the hospital LIS, this system is quick, efficient, and cost effective. The on-going development of new assays to meet the growing demands of the healthcare market ensures a growing portfolio of tests will be available for this system during 2019 and beyond.

The Standard F system can be seen on the Oxford Biosystems stand at IPC 2019 London.


Other news

Upcoming Events

BSA Annual Conference 2019: Translating Research into Practice

Molineux Stadium, Wolverhampton
Wednesday 5th June

Sepsis + Conference 2019

National Conference Centre Birmingham
11th June

Knowlex: Patient Safety 2019

NCC Birmingham
11th June 2019

BSG Annual Meeting 2019

Monday 17th June to Thursday 20th June 2019

AfPP Residential 2019

York University
8th to the 11th August

Latest Issue

Clinical Services Journal

Clinical Services Journal

May 2019

Improving safety for both staff and patients

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Apr 2019

Putting patients and hospitals first

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.